Basic & Clinical Pharmacology & Toxicology最新文献

{"title":"Eugenol Alleviates Cerebral Ischemia–Reperfusion Injury in Mice by Promoting the Phagocytosis of Microglia via Up-Regulating Tripartite Motif Protein 59","authors":"Mengtian Pan,&nbsp;Xiang Li,&nbsp;Xinjuan Tian,&nbsp;Lele Zixin Yang,&nbsp;Weirong Fang","doi":"10.1111/bcpt.70058","DOIUrl":"https://doi.org/10.1111/bcpt.70058","url":null,"abstract":"<div>\u0000 \u0000 <p>Ischemic stroke (IS) is one of the most sinister diseases and the second leading cause of death in the world. Eugenol (EUG) is a natural and biologically active component that can be extracted from various plants. Studies have found that EUG can alleviate middle cerebral artery occlusion and reperfusion (MCAO/R) injury in mice, but the specific mechanism remains vague. Tripartite motif protein 59 (TRIM59) is a member of TRIM protein family, a group of E3 ubiquitin ligases. In this article, we conducted both in vivo and in vitro experiments to determine the effect of EUG on ischemia–reperfusion injury and to explore the underlying mechanisms by manipulating the expression of TRIM59. Results showed that EUG alleviates acute injury and promotes functional repair of mouse IS by enhancing the phagocytosis of microglia through up-regulating the TRIM59, activating the STAT3 pathway and promoting the expression of CD11b.</p>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare Providers' Perspectives on Antidepressant Discontinuation: A Focus Group Study","authors":"S. Bouarfa,&nbsp;Wilma Göttgens,&nbsp;Suzanne A. Ligthart,&nbsp;Otto R. Maarsingh,&nbsp;Christiaan H. Vinkers,&nbsp;Henricus G. Ruhé,&nbsp;Pierre M. Bet,&nbsp;Jacqueline G. Hugtenburg","doi":"10.1111/bcpt.70051","DOIUrl":"https://doi.org/10.1111/bcpt.70051","url":null,"abstract":"<p>Antidepressant (<span>AD</span>) discontinuation in long-term users can be challenging for both patients and healthcare providers (HCPs). Better understanding of how HCPs handle this challenge is needed to improve discontinuation care. Therefore, we identified <span>AD</span> discontinuation barriers and facilitators from the viewpoint of community pharmacists (CPs), general practitioners (GPs), psychiatrists and nurse practitioners and explored their views on their specific roles in <span>AD</span> discontinuation. Two focus group discussions involving four GPs, six pharmacists and three psychiatrists and one interview with a nurse practitioner were performed. Discussions were recorded and transcribed verbatim. Directed content analysis was performed using the theoretical domains framework. Six themes were identified: identification of patients, behaviour of HCPs regarding <span>AD</span> discontinuation, fears and emotions, context and resources, knowledge, evidence and skills and professional attitude. All HCPs stressed the importance of raising awareness for <span>AD</span> discontinuation. Barriers included fear of recurrence or discontinuation symptoms, poor collaboration between HCPs and lack of resources. Facilitators included the availability of tools and guidelines. HCPs were unaware and uncertain about each other's roles and responsibilities and showed motivation to provide guidance. This requires professional collaboration agreements and sufficient resources. Experienced CPs may contribute by identifying <span>AD</span> users and providing information/support.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70051","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Proton-Pump Inhibitor Use Among Danish Adults: A Nationwide Drug Utilization Study 2015–2023","authors":"Karoline M. Lundgaard,&nbsp;Morten Ø. Christiansen,&nbsp;Heidi Sonne,&nbsp;Katrine Mose,&nbsp;Nikolaj Nyland,&nbsp;Maja J. L. Andersen,&nbsp;Anton Pottegård","doi":"10.1111/bcpt.70057","DOIUrl":"https://doi.org/10.1111/bcpt.70057","url":null,"abstract":"<p>The global increase in proton-pump inhibitor (PPI) use has raised concerns about their appropriate use, particularly due to potential overprescription and associated adverse effects. This study examines PPI utilization patterns among Danish adults from 2015 to 2023 using the Danish nationwide health registries. We estimated the annual incidence rate (users per 100 person-years) and monthly prevalence (proportion with a filled prescription or sufficient tablets). Treatment duration was assessed using the ‘proportion of patients covered’ and the Kaplan–Meier method. We also calculated the proportion of adults with concomitant use of ulcerogenic drugs over time. We identified 1 729 440 adults who filled at least one PPI prescription during 2015–2023. The prevalence increased from 7.0% in 2015 to 8.2% in 2023, while incidence rate remained stable at ~3 users per 100 person years. PPI use increased with age. Three years after initiation, 17% used PPIs, while 1.5% had remained on continuous treatment. In 2023, 50% of users had concomitant ulcerogenic drug use, a 3.2% increase since 2015. The prevalence of PPI use in Denmark has risen markedly reaching a high stable level, with a clear age-dependent trend. Increased attention to appropriate PPI use is necessary to ensure rational prescribing and prevent potential overuse.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70057","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deprescribed or Discontinued? Addressing Terminology Misinterpretation in Research","authors":"Caroline Sirois,&nbsp;Alexandre Campeau Calfat,&nbsp;Justin P. Turner","doi":"10.1111/bcpt.70054","DOIUrl":"https://doi.org/10.1111/bcpt.70054","url":null,"abstract":"","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 6","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TCA Cycle Intermediate Mitigates Di(2-ethylhexyl) Phthalate-Induced Cholestatic Liver Injury Through Modulation of the Nrf2/NQO1 Signalling Axis","authors":"Yue Jiang,&nbsp;Fang Xie,&nbsp;Xutao Ling,&nbsp;Jiayi Zhang,&nbsp;Yun Yu,&nbsp;Qianqian Huang,&nbsp;Lun Zhang,&nbsp;Lu Ye,&nbsp;Wenkang Tao,&nbsp;Mengzhen Hou,&nbsp;Cheng Zhang,&nbsp;Jianqing Wang","doi":"10.1111/bcpt.70047","DOIUrl":"https://doi.org/10.1111/bcpt.70047","url":null,"abstract":"<div>\u0000 \u0000 <p>As a commonly used phthalate compound, di(2-ethylhexyl) phthalate (DEHP) has been shown to disrupt the tricarboxylic acid (TCA) cycle and aggravate tissue damage. However, whether the TCA cycle is involved in cholestatic liver injury (CLI) induced by DEHP and the protective effect of dimethyl fumarate (DMF), which is used to supplement TCA intermediate metabolites, remained unclear. Here, mice were randomized into five groups (<i>n</i> = 6/group): (1) Control, (2) DEHP (200 mg/kg/day), (3) DMF (100 mg/kg/day), (4) DEHP + DMF (30 mg/kg/day) and (5) DEHP + DMF (100 mg/kg/day). Our data demonstrated that DEHP exposure upregulated total bile acid (TBA) levels and broke the TCA cycle, resulting in reduced fumaric acid and malic acid. However, we further supplemented fumaric acid with DMF and found that DMF effectively reversed the high levels of TBA, alkaline phosphatase (ALP) and glutamyl transpeptidase (GGT) induced by DEHP in mice. Meanwhile, pathological results in the liver showed that DMF improved bile duct cell damage, inflammatory cell infiltration, collagen deposition and necrosis caused by DEHP. In addition, we found that DEHP elevated the level of interleukin (IL)-1β, IL-6, TNF-α and MDA and decreased the level of SOD in the mouse liver, which was effectively reversed by DMF treatment. Besides, DMF upregulated the expression of Nrf2 and NQO1 in the liver of DEHP-exposed mice. For in vitro validation, AML-12 cells were treated with (1) Control, (2) DEHP (250 μM), (3) DEHP + DMF (10 μM), (4) DEHP + DMF (25 μM) and (5) DEHP + DMF (50 μM). DEHP exposure increased the expression of IL-1β, IL-6 and TNF-α, which was mitigated by DMF, while ML385, an Nrf2 inhibitor, could counteract the anti-inflammatory effects of DMF. These findings indicate that DEHP broke the TCA cycle of the mouse liver, and DMF supplementation protects against DEHP-induced CLI by activating the Nrf2/NQO1 pathway.</p>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 6","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143950216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to ‘Initiation of Anticoagulants During the COVID-19 Pandemic in Sweden: An Interrupted Time Series Analysis’","authors":"","doi":"10.1111/bcpt.70055","DOIUrl":"https://doi.org/10.1111/bcpt.70055","url":null,"abstract":"<p>\u0000 <span>P.-J. Samuelsen</span>, <span>B. Wettermark</span>, <span>F. Nyberg</span>, <span>M. Hajiebrahimi</span>, “ <span>Initiation of Anticoagulants During the COVID-19 Pandemic in Sweden: An Interrupted Time Series Analysis</span>,” <i>Basic &amp; Clinical Pharmacology &amp; Toxicology</i> <span>136</span>, no. <span>2</span> (<span>2025</span>): e14119, https://doi.org/10.1111/bcpt.14119.\u0000 </p><p>In the article cited above, several discrepancies occurred between the final author-approved manuscript and the published version.</p><p>\u0000 <b>Confidence intervals</b>\u0000 </p><p>\u0000 <b>In-text citation corrections</b>\u0000 </p><p>\u0000 <b>Reference list corrections</b>\u0000 </p><p>Reference [32] cited a corrigendum instead of the original guideline. The correct reference is:</p><p>G. Hindricks, T. Potpara, N. Dagres, et al., “2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC,” <i>European Heart Journal</i> 42, no. 5 (2021): 373–498, https://doi.org/10.1093/eurheartj/ehaa612.</p><p>In addition, seven references contained minor inaccuracies. The corrected references are listed in the table below:\u0000 </p><p>These corrections do not affect the conclusions of the article. We apologize for this error.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 6","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70055","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rutin-Associated Hepatoprotection: A Review of Mechanisms and Therapeutic Prospects","authors":"Yanting Feng,&nbsp;Lanchun Peng,&nbsp;Xiaohui Liu,&nbsp;Qingzhu Zheng,&nbsp;Min Qian,&nbsp;Meiling Deng,&nbsp;Jiangli Peng,&nbsp;Yamei Li,&nbsp;Limei Lin,&nbsp;Qiuxian Peng","doi":"10.1111/bcpt.70042","DOIUrl":"https://doi.org/10.1111/bcpt.70042","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Liver disorders pose a considerable global health challenge, accompanied by rising mortality rates. Current therapeutic strategies, though effective, often face limitations due to adverse effects and therapeutic resistance, prompting the exploration of alternative treatments, particularly safer natural compounds. Rutin, a widely available bioflavonoid, has emerged as a promising candidate owing to its varied pharmacological properties.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a comprehensive search on PubMed and Web of Science using the following keywords: ‘rutin’, ‘liver diseases’, ‘hepatoprotection’, ‘clinical observations’, ‘mechanisms, pharmacology’ and various combinations of these terms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This review systematically examines rutin's therapeutic potential in hepatic disorders, focusing on its molecular mechanisms, particularly its effects on inflammatory pathways, oxidative stress and hepatocellular protection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We analyse existing evidence supporting rutin's hepatoprotective efficacy, identify its cellular and molecular targets and evaluate its potential applications in various liver diseases. Our systematic analysis provides theoretical support for developing rutin-based therapies in hepatic disease management and identifies future research directions and clinical applications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 6","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70042","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143939546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in the Inflammatory Response and Corticoid Responsiveness of Human Lung Macrophages and Parenchymal Explants Exposed to Cigarette Smoke Extracts","authors":"Marion Brollo,&nbsp;Quentin Marquant,&nbsp;Hélène Salvator,&nbsp;Justine Cohen,&nbsp;Matthieu Glorion,&nbsp;Alexis Ferré,&nbsp;Martin Dres,&nbsp;Nicolas Roche,&nbsp;Stanislas Grassin-Delyle,&nbsp;Philippe Devillier","doi":"10.1111/bcpt.70046","DOIUrl":"https://doi.org/10.1111/bcpt.70046","url":null,"abstract":"<p>Smoking is the main cause of chronic obstructive pulmonary disease (COPD) and is associated with corticosteroid resistance. Given the paucity of data on human lung preparations, macrophages (LMs), and parenchymal explants (LPEs) were exposed to cigarette smoke extracts (CSE) in the presence or absence of lipopolysaccharide (LPS). Moreover, LMs and LPEs were treated with budesonide prior exposure to CSE or LPS. The levels of cytokines (TNF-α, IL-6) and chemokines (CCL2, CCL4, CXCL1, CXCL5, and CXCL8) in the supernatants were measured using ELISAs.</p><p>In LMs, exposure to CSE was not associated with significant difference in the production of cytokines and chemokines, with the notable exception of greater CXCL8 production. The results were generally the same for LPEs. CSE exposure did not potentiate the LPS-induced production of the cytokines and chemokines and even tended to reduce this production in LMs and LPEs. Lastly, CSE exposure inhibited budesonide’s anti-inflammatory activity in LMs but not in LPEs.</p><p>This study extends the data on the CSE inflammatory effects and its inhibition of corticosteroid efficacy in human lung preparations. Our findings question the relevance of these preparations with regard to the long-term toxicity of smoking and the corticosteroid resistance observed in smokers and in patients with COPD.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 6","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70046","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143925898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Potential Ability of Betulinic Acid to Prevent Experimentally Induced Acute Pancreatitis in Rats","authors":"Guler Yenice,&nbsp;Seckin Ozkanlar,&nbsp;Ismail Bolat,&nbsp;Serkan Yildirim","doi":"10.1111/bcpt.70052","DOIUrl":"https://doi.org/10.1111/bcpt.70052","url":null,"abstract":"<p>Acute pancreatitis (AP) is a serious pancreatic inflammatory disease that results in pancreatic enzyme activation and autodegradation. Betulinic acid (BA), a pentacyclic triterpene of natural origin that was isolated from several plants, has anti-inflammatory, immunomodulatory and antioxidant effects that can help with AP. With this study, we aimed to investigate the potential positive effects of BA on <span>l</span>-arginine-induced AP. A total of 24 male rats were divided into four groups (control, BA, AP and BA + AP). Animals in the BA group were given BA 50 mg/kg/day for 7 days. AP was induced by administering two doses of 250-mg/100-g <span>l</span>-arginine to animals in the AP group. The animals in the BA + AP group were administered 50-mg/kg/day BA (gavage) for 7 days and two doses of 250-mg/100-g <span>l</span>-arginine on the seventh day. BA pretreatment inhibited the increased lipase activity caused by AP and showed protective activity against oxidative damage to pancreatic tissue. It decreased the severity of inflammation by suppressing the release of pro-inflammatory cytokines while increasing the level of the anti-inflammatory cytokine IL-10. It showed a protective effect on pancreatic tissue by inhibiting tumour necrosis factor (TNF-α) and Bax expression. The findings of the study show that BA exhibits multifaceted protective activity in experimental AP induced with <span>l</span>-arginine.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 6","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70052","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143925899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergency Department Visits due to Medication Overdose in a Finnish University Hospital","authors":"Sami Mustajoki,&nbsp;Aleksi Reito,&nbsp;Kalle Peltonen","doi":"10.1111/bcpt.70053","DOIUrl":"https://doi.org/10.1111/bcpt.70053","url":null,"abstract":"<p>There are no recent reports from the Nordic countries describing emergency department (ED) visits due to medication overdose.</p><p>All patients visiting EDs of Tampere University Hospital, Finland, with ICD-10 codes T36–T50.9 during the year of 2021 were included in this study.</p><p>A total of 803 ED visits by 631 individual patients were identified, comprising 0.7% of all ED visits in 2021. The intention of the overdose was self-harm in 70%, inebriation in 17% and other in 13% of the visits. The mean age of the patients was 35 (range 1–95) years, and 63% were female. In 52% of the visits, the patient had taken more than one medication. Benzodiazepines were involved in 40% of the visits, followed by antipsychotics (28%), antidepressants (19%), paracetamol (15%) and opiates (13%). Twenty-six percent of the patients were admitted to the intensive care or high-dependency care unit, but there were no overdose-related in-hospital deaths. The overall 1-year mortality rate after an overdose was 2.8%.</p><p>The intention of a medication overdose was most often self-harm, followed by inebriation. Over half of the overdoses were multidrug overdoses, and psychoactive medications were predominantly used. There were no in-hospital deaths related to medication overdoses.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 6","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70053","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143909450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}